The development of anticoagulants started in the 1930s with the discovery and availability of parenteral heparin. In the 1950s, oral vitamin K antagonists found their way into clinical therapeutics. Although both components are flawed with considerable limitations such as a narrow therapeutic window, an unpredictable anticoagulatory effect, drug-interactions and the necessity of continuous aPTT/INR-monitoring, they have been the only anticoagulants for prophylaxis and therapy of thromboembolic disorders for several decades [Alban, 2005] . The first step toward more predictable anticoagulatory activity of unfractionated heparin (UFH) was the development of low molecular weight heparins (LMWHs) in the 1980s. This family of heparins features a higher ratio of anti-Xa and anti-IIa activity, lower plasma protein interactions and renal elimination and, as a consequence, they do not require routine monitoring of their antithrombotic effect. Today, enoxaparin and dalteparin are the only LMWHs which are also indicated for use in patients with unstable angina/NSTEMI, STEMI with percutaneous coronary intervention (PCI) (enoxaparin) and in combination with aspirin for patients with unstable angina/NSTEMI (dalteparin) [Anderson et al. 2007] . Aspirin therapy is still a cornerstone of antiplatelet therapy in cardiovascular medicine since the early 1980s when the Veterans Administration Cooperative Study revealed significantly protective effects, reducing nonfatal myocardial infarction and the combined endpoint of death or myocardial infarction (MI), by 51% [Lewis et al. 1983] . Aspirin therapy in combination with P2Y12-inhibition with clopidogrel (which binds highly selectively to the P2Y12receptor on the surface of platelets and selectively blocks ADP-induced platelet aggregation) is today still the recommended platelet inhibitory treatment regimen for patients presenting with an acute coronary syndrome (ACS) and in those undergoing PCI and stent implantation [Anderson et al. 2007] . Although undoubtedly beneficial in reducing the risk for adverse thrombotic events in a broad range of cardiovascular patients, we are nowadays more and more recognizing several limitations to this treatment regimen: On the one hand, 1540% of patients are poor responders to treatment, as evaluated by ADP-induced platelet aggregation and several trials show that such patients are at increased risk of stent thrombosis, MI and death [Wallentin, 2009] . On the other hand, the risk for bleeding is substantially increased by dual antiplatelet therapy. Assuming a baseline risk for major bleeding of 1.9% over a 13 month period based on the mean event rate in patients treated with aspirin alone in the 4 longer term clinical trials, an 80% increase in the odds of major bleeding is equivalent to an absolute risk increase of 1.5% [Bowry et al. 2008] . In other words, the number needed to treat (NNT) for 13 months to cause one additional major haemorrhage is only 66. It is assumed today that the use of dual therapy in patients with acute coronary syndrome (ACS), especially in the acute phase, has a favourable risk/benefit ratio, whereas in stable patients with cardiovascular disease, it is associated with an increased risk for bleeding [Eshaghian et al. 2007] .
In this issue of the journal, Fauler nicely reviews the clinical pharmacology of antithrombotic drugs in coronary artery disease [Fauler, 2009] with a focus on already established therapies. In the last decade, a variety of novel anticoagulant and antiplatelet agents that improve outcomes in patients undergoing percutaneous coronary revascularization has emerged. Several of them are still under development. During the next decade, continued refinements in catheter-based device technology should lead to further increases in the number of interventional procedures requiring improved therapeutic performance of antiplatelet strategies. In the late 1980s and 1990s, indirect factor Xa-inhibitors such as fondaparinux and idraparinux (parenteral), direct thrombininhibitors such as bivalirudin (parenteral) and dabigatran (per os) became available. Fondaparinux has anti-ischemic properties similar to enoxaparin but has a lower bleeding risk. Bivalirudin is an emerging new drug that offers similar anti-ischemic properties to unfractionated heparin (UFH) combined with a GPIIb/IIIa antagonist (e.g. abciximab, eptifibatide, tirofiban which abolish platelet aggregation by binding to GPIIb/IIIa-receptors on a platelet's surface at approximately 80% receptor blockade) but has the advantage of fewer bleeding complications (please see table I for detailed drug overview). The latest step in the development of anticoagulants with a more comfortable clinical handling was the development of direct factor Xa antagonists which are independent of AT III. Otamixaban is an intravenous, selective, short-acting FXa inhibitor that has been investigated in the Study to Evaluate the Pharmacodynamics, the Safety and Tolerability, and the Pharmacokinetics of Several Intravenous Regimens of the Factor Xa Inhibitor Otamixaban, in Comparison to Intravenous Unfractionated Heparin in Subjects Undergoing Non-urgent Percutaneous Coronary Intervention (SEPIA-PCI) [Cohen et al. 2007] . The results of this study were recently reported: the most promising results were seen with intermediate doses of otamixaban (0.105 and 0.14 mg/kg per h): the rates of the primary outcome were lower than that with heparin plus eptifibatide, and the rates of thrombotic complications during PCI were similar. Otamixaban was associated with a significant dose-dependent increase in the primary safety outcome, TIMI major or minor bleeding (the thrombolysis in myocardial infarction classification divides bleeding into major, minor, or minimal events according to intracranial hemorrhage, hemaglobin concentration and fall in hematocrit), but the bleeding rates with intermediate doses of otamixaban were similar to those with heparin plus eptifibatide [Sabatine et al. 2009 ]. For long-term FXa inhibition, intravenous treatment is not feasible. Therefore, orally active anti-Xa-agents such as rivaroxaban or apixaban have been developed. Rivaroxaban has been tested in ACS patients in the ATLAS TIMI 46 trial and was associated with a non-significant 21% relative risk reduction (RRR) for the primary efficacy endpoint death, MI, stroke or severe recurrent ischemia requiring revascularization and a significant 31% RRR for the secondary endpoint (death, MI or stroke), demonstrating a trend for efficacy across doses [Mega et al. 2009 ]. Apixaban is also an oral direct factor Xa-antagonist and has so far completed a phase II dose-finding-trial in ACS patients (APPRAISE I): a dose-related increase in bleeding and a trend toward a reduction in ischemic events with the addition of apixaban to antiplatelet therapy in patients with recent acute coronary syndrome was reported and the study authors concluded that safety and efficacy of this drug may vary depending on background antiplatelet therapy [Alexander, 2009] . Table 1 provides a brief overview of the main therapeutic advantages and disadvantages of already established compared with newer antithrombotic drugs still in clinical development.
Four therapeutically important issues underscored by very recent results from clinical trials deserve specific attention and comment:
(1) Clopidogrel hyporesponsiveness or resistance This phenomenon has been reported to be associated with post-PCI major adverse cardiac events (MACE) [Bliden et al. 2007] . One strategy to overcome this problem might be to increase the dose of the thienopyridine. During a hot session at the European Society of Cardiology (ESC) Congress 2009 in Barcelona, Mehta reported new results from the CURRENT-OASIS-7 study: doubling the loading (600 mg) and maintenance doses of clopidogrel (150 mg/d) in ACS patients undergoing planned PCI significantly reduced stent thrombosis (RRR: 42%, p < 0.001) and cardiovascular events (RRR: 15%, p < 0,036), largely driven by reductions in MI, without a significant increase in major bleeding. However, patients not undergoing PCI did not profit from this regimen and suffered an increase in bleeding as adverse events. Interestingly, there was neither benefit, nor increase in bleedings seen in the study arm increasing the dose of acetyl salicylic acid (ASA) up to 300325 mg/d. Based on these results it seems reasonable to increase the dose of clopidogrel in patients with ACS scheduled for PCI, especially in high risk patients for thromboembolic events and in patients with already known hyporesponsiveness or resistance to clopidogrel. The difference in the response to the double dose clopidogrel drug regimen between patients undergoing PCI and those who do not might be attributed to a still more activated clotting cascade caused by the interventional procedure. This increased procoagulatory condition might be compensated by doubling the dose of clopidogrel in the PCI group whereas patients with ACS not undergoing PCI lack this additional procoagulatory stimulus and are therefore overtreated with the higher dose of clopidogrel and therefore suffer increased bleeding rates.
(2) Pharmacologic interactions reducing the efficacy of clopidogrel (a) Interaction of clopidogrel with PPIs (proton pump inhibitors). A problem resulting in potentially relevant reduced anticoagulatory efficacy of clopidogrel and also prasugrel in patients being coadminstered a PPI has deserved considerable clinical attention. Both clopidogrel and prasugrel are prodrugs that are metabolized by the CYP P450-system in the liver (mainly by CYP2C19) to form their active metabolites. Prasugrel achieves greater and more consistent platelet inhibition than standard doses or higher doses of clopidogrel [Jernberg et al. 2006 , Brandt et al. 2007 , a difference that might be explained in part by a more efficient conversion of prasugrel into its active metabolite [Brandt et al. 2007] . Considerable concern has been raised that PPIs with CYP2C19-inhibiting potency (mainly omeprazole, but in a limited extent also esomeprazole, rabeprazole and lansoprazole) might diminish the antiplatelet effects of clopidogrel and its clinical efficacy because coadministration of clopidogrel with a CYP2C19-inhibiting PPI, especially omeprazole, might lead to a reduced conversion of clopidogrel into its active metabolite. It is indeed correct that platelet response to clopidogrel after coronary stenting due to an ACS is significantly reduced. A recent study aiming to compare the effects of two different PPIs, omeprazole (CYP2C19-inhibiting) and pantoprazole (no relevant cytochrome inhibition), revealed that patients receiving pantoprazole had a significantly better platelet response compared to patients being coadministered omeprazole [Cuisset et al. 2009 ]. However, O'Donoghue and colleagues retrospectively reviewed data from two large clinical trials of patients with acute coronary syndroms (PRINCIPLE-TIMI and TRITON-TIMI; n ¼ 13809 patients) and assessed the association between PPI use, measures of platelet function, and clinical outcomes for patients treated with clopidogrel or prasugrel [O'Donoghue, et al. 2009] : No association existed between PPI use and risk of the primary endpoint for patients receiving either clopidogrel or prasugrel. Based on the results of these two very recent studies it seems logical to prefer pantoprazole over omeprazole if concomitant PPI-TPD-therapy is necessary but also suggests that the likelihood of causing a serious clinical problem in terms of an acute vascular event triggered by this drug interaction is rather limited.
(b) Interaction between clopidogrel and phenprocoumon. A second problem is a recently reported interaction between clopidogrel and phenprocoumon. Sibbing presented preliminary results at the ESC 2009 stating that phenprocoumon significantly attenuates the antiplatelet effects of clopidogrel [Sibbing, 2009] . The researcher measured platelet aggregation in around 1000 consecutive patients who were taking chronic antiplatelet treatment with aspirin and clopidogrel and attended a follow-up appointment a median of seven months after coronary stenting. ADP-induced platelet aggregation was assessed under steady-state conditions with multiple electrode-platelet-aggregometry. Results showed that patients taking concomitant phenprocoumon had a significantly attenuated response to clopidogrel as compared with patients not taking phenprocoumon, and this attenuated response was still present in a multivariate analysis adjusting for comedication (such as PPI treatment), comorbidities, and other known predictors of clopidogrel low responsiveness. However, it still needs to be clarified to which amount this drug interaction might contribute to an increase in adverse cardiovascular events in patients on both drugs clopidogrel and phenprocoumon. An answer to this question is eagerly awaited.
(3) Is the new P2Y12-antagonist ticagrelor superior to the established first generation TPD clopidogrel?
The PLATO trial comparing ticagrelor (180 mg/ d loading + 90 mg/d twice) versus clopidogrel (300600 mg loading + 75 mg/d) in patients with ACS significantly reduced the rate of death from vascular causes, myocardial infarction or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding ]. The rate of definite stent thrombosis was lower in the ticagrelor group than in the clopidogrel group (1.3% vs 1.9%, p ¼ 0.009). These results suggest considerable therapeutic potential for ticagrelor as new P2Y12-antagonist substituting the established TPD clopidogrel. Ticagrelor provides a stronger and more rapid antiplatelet effect than clopidogrel. However, there are some serious concerns with respect to the adverse-event profile of this new drug such as dyspnea, bradyarrhythmia, ventricular pauses >3 seconds, uric acid increases and increases in intracranial bleeding events (Table 1) , which need to be carefully assessed in future phase III trials and might reduce the therapeutic potential of the substance.
(4) What is the therapeutic role of the new thrombin antagonists in ACS? Dabigatran is being developed for treatment of patients with ACS and a phase II dose-findingstudy (RE-DEEM, NCT00621855) is ongoing for this indication. The results of the recently published RELY study [Connolly et al. 2009] investigating the risk of stroke in patients with atrial fibrillation versus warfarin as comparator showed promising results: Dabigatran given at doses of 150 mg twice daily prevented more strokes and dabigatran at a dose of 110 mg twice daily caused fewer haemorrhages. A potential value for the therapeutic use of dabigatran in ACS cannot be predicted from the results of this trial. Because of important drug interactions P-glycoprotein-inhibitors including verapamil, amiodarone and quinidine raise dabigatran serum concentrations considerably the risk of haemorrhage is increased in such patients on dabigatran. The fact that in RE-LY, rates of dyspepsia including abdominal pain were elevated with dabigatran (11.8% vs 5.8% in the warfarin group) requires caution. Upcoming phase III trials will have to show if dabigatran is useful in patients with ACS.
What is the quintessence for the practicing physician? Both antiplatelet and antithrombotic medications are essential components of established and guideline-recommended treatment regimens in coronary heart disease. However, combined use is more effective but also results in an increased bleeding risk. With respect to aspirin, the most appropriate dosing strategy appears to be 100 mg to maximize efficacy and to minimize bleeding risk. Doses of aspirin higher than 100 mg are associated with an increased risk of bleeding without any greater benefit as compared with doses <100 mg [Campbell et al. 2007] and should therefore be withheld. Dual antiplatelet therapy for 312 months results on the one hand in a 20% relative risk reduction in the composite endpoint of death, MI and stroke. On the other hand, the risk for major bleedings is significantly increased (14%), especially in patients undergoing coronary artery bypass grafting surgery (CABG). Therefore, clopidogrel should be withheld for 5 days before CABG [Rao, 2009] . In high-risk patients for thromboembolic events and in patients with already known hyporesponsiveness or resistance to clopidogrel, doubling the loading dose (to 600 mg/d) and the maintenance dose (to 150 mg/d) might outweigh the increased risk of bleeding in patients with ACS scheduled for PCI, whereas the practical clinical relevance of drug interactions of clopidogrel with PPIs seems to be rather limited. The potential clinical relevance of the interaction between clopidogrel and phenprocoumon still needs to be elucidated but should be kept in mind yet.
Finally, how can we judge the therapeutic potential of the new second-generation TPD prasugrel to replace clopidogrel as today's gold standard? Prasugrel inhibits platelet aggregation faster, more profoundly and more reliably compared with clopidogrel, which results in a 19% risk reduction for atherothrombotic events at the cost of a higher bleeding risk (relative increase: 30%; fatal hemorrhage: 0.3% vs 0.1% for clopidogrel [Unger, 2009] ). Therefore, high-risk patients such as patients undergoing PCI for STMI, patients at high risk of stent thrombosis and diabetics undergoing PCI might be candidates for the new drug. However, it must be strongly underlined that the risk of CABG-related bleeding is much higher with prasugrel (14.1% with prasugrel vs 4.5% with clopidogrel; fatal hemorrhage in older patients >75 years: 1% vs. 0.1% with clopidogrel [Unger, 2009] ) due to its greater antiplatelet effect. It is neither known whether withholding prasugrel before CABG would reduce the bleeding risk, nor how long before surgery prasugrel would need to be discontinued to minimize surgery-related hemorrhagic complications. Therefore, when making a therapeutic decision in favour of prasugrel, caution is highly warranted, especially in older patients and in patients undergoing CABG-surgery.
